KPIs & Operating Metrics(New)
Animal Health Revenue BreakdownBreakdown Of AssetsEmployee StatisticsGross Margin %Gross ProfitGross Profit AnnualGross Profit Annual %InventoriesLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of Total Revenue %Pharmaceuticals Revenue BreakdownPharmaceuticals Revenue Breakdown AnnualPrice Change By Region %Price Change By Region Annual %Price, Volume & Rate Change Total %Property And Equipment SegregationRate Change By Region %Rate Change By Region Annual %Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By Customer LocationRevenue By Customer Location %Revenue By Customer Location AnnualRevenue By Customer Location Annual %Revenue By RegionRevenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Volume Change By Region %Volume Change By Region Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Gross Profit (2009 - 2026)

Eli Lilly posted quarterly Gross Profit of $16.2 billion for Q1 2026, up 54.44% year-on-year from $10.5 billion in Q1 2025, and up 1.9% on a QoQ basis from $15.9 billion in Q4 2025.

Eli Lilly (LLY) has 18 years of Gross Profit data on file, last reported at $16.2 billion in Q1 2026.

  • For the quarter ending Q1 2026, Gross Profit rose 54.44% year-over-year to $16.2 billion; the trailing twelve-month figure through Mar 2026 stood at $59.8 billion (up 49.48% YoY), and the FY2025 full-year result was $54.1 billion, up 47.79% from the prior year.
  • Gross Profit for Q1 2026 stood at $16.2 billion, up from $15.9 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $16.2 billion in Q1 2026 and bottomed at $5.1 billion in Q2 2022.
  • The 5-year median for Gross Profit is $7.6 billion (2023), against an average of $9.2 billion.
  • The widest annual swing landed in 2023, when Gross Profit dropped 7.05%; it then soared 57.45% in 2025.
  • A 5-year view of Gross Profit shows it stood at $5.8 billion in 2022, then jumped by 31.49% to $7.6 billion in 2023, then soared by 47.11% to $11.1 billion in 2024, then soared by 43.04% to $15.9 billion in 2025, then gained by 1.9% to $16.2 billion in 2026.
  • The last three Gross Profit figures came in at $16.2 billion (Q1 2026), $15.9 billion (Q4 2025), and $14.6 billion (Q3 2025), per Business Quant data.